Navigation Links
Cambrex Reports Third Quarter 2009 Results
Date:11/3/2009

l until the third quarter 2009 Form 10-Q is filed with the SEC.

Basis of Reporting

The Company has provided a reconciliation from adjusted and other non-GAAP amounts to GAAP amounts at the end of this press release. Management believes that this basis of reporting provides a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain recorded expenses.

Conference Call and Webcast

The Conference Call to discuss third quarter 2009 results will begin at 8:30 a.m. Eastern Time on Wednesday, November 4, 2009 and last approximately 45 minutes. Those wishing to participate should call 1-888-634-4003 for domestic and +1-706-634-6653 for international. Please use the pass code 37211896 and call approximately 10 minutes prior to start time. A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call. A telephone replay of the conference call will be available through Wednesday, November 11, 2009 by calling 1-800-642-1687 for domestic and +1-706-645-9291 for international. Please use the pass code 37211896 to access the replay.

Forward Looking Statements

This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates
'/>"/>

SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... ChemoCentryx, Inc. today announced that it ... clinical trial of CCX354, an orally-bioavailable, novel, small ... chemokine receptor for the treatment of rheumatoid arthritis ... and selective antagonist of CCR1, a chemokine receptor ... as monocytes and macrophages, associated with the inflammation ...
(Date:12/15/2009)... Cellular Dynamics International (CDI) ... for use in testing of new drug candidates ... cells are designed to aid drug discovery and ... toxicity screens, weeding out ineffective and potentially toxic ... significant time and resources have been invested. ...
(Date:12/15/2009)... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... 15, 2009 special dividend payment of $1.67 per share ... December 1, 2009. With this payment, distributions to ... $2.67 per share. In January 2010, the Company ... of the Company,s 2009 cash distributions and the allocation ...
Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4PDL BioPharma Completes December 15 Special Dividend Payment 2Baucus Bill Integrates Physician Assistants in Health Care Delivery 57564 1Baucus Bill Integrates Physician Assistants in Health Care Delivery 57564 2NeurogesX to Present at UBS Global Life Sciences Conference 14133 1NeurogesX to Present at UBS Global Life Sciences Conference 14133 2NeurogesX to Present at UBS Global Life Sciences Conference 14133 3deCODE Receives Nasdaq Bid Price Deficiency Notice 14131 1deCODE Receives Nasdaq Bid Price Deficiency Notice 14131 2deCODE Receives Nasdaq Bid Price Deficiency Notice 14131 3
... Begins October 1, 2007, WOONSOCKET, R.I., Sept. 19 ... healthy this winter by offering,flu vaccinations in over 4,000 ... will begin in select markets on October 1, 2007 ... customers may,call 1-800-SHOP-CVS and choose option #1, or visit ...
... B. and Lynne,V. Cheney Cardiovascular Institute and ... George Washington University host a cutting edge,Symposium ... the growing forces,of genomics and personalized medicine ... a valuable state-of-the-art update on the current,status ...
Other Medicine Technology:CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores 2Personalized Medicine - The Genomic Revolution in Cardiac Care 2Personalized Medicine - The Genomic Revolution in Cardiac Care 3
(Date:12/16/2009)... be determining factor for use, expert says, , , WEDNESDAY, ... failure are much less likely to die when they ... , The study included 4,685 people, ages 65 to ... a left ventricular fraction (a measure of the heart,s ... a three-year period, those who were treated with standard ...
(Date:12/16/2009)... SAN FRANCISCO, Dec. 16 Shoppers like ... States, Mexico or Argentina. But grocers have found ... Origin Labeling (COOL) laws requiring them to provide ... specific website at easyCOOLnow.com for easily ... COOL laws include provisions that require retailers of ...
(Date:12/16/2009)... 16 A new software program developed by ... healthcare facilities to calculate their staffing needs as it ... allows inpatient healthcare facilities to calculate their mandatory ... ratios and receive a daily report as to how ... a leader in risk management in the healthcare industry, ...
(Date:12/16/2009)... Dec. 16 In a random sampling ... Portland, ME, and Philadelphia, PA, numerous pallets tested ... bacteria that could potentially create health hazards for ... of previous wood pallet testing conducted in the ... unacceptable risks to our nation,s food supply from ...
(Date:12/16/2009)... is at the heart of diagnostic procedures in cardiology. ... Imaging which accumulates the expertise of European cardiovascular imagers, ... in that it is written with a patient rather ... to the patient, with the aid of imaging. ... specific themes involving theory and practice of cardiac imaging ...
Breaking Medicine News(10 mins):Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3
... of Australia & New Zealand, a panel of researchers has ... allowed to die naturally, while those born at 24 weeks ... Lui, a senior lecturer in the School of Women's and ... group of doctors, nurses and parents that developed the recommendations, ...
... has shown that people who suffer whiplash injuries can ... widely used in Quebec, Canada.// The Whiplash Management strategy ... highlights of this initiative being better cost economy and ... ,The stipulation will target, better practices in management of ...
... University of California finds that vitamin D can have a hand ... of vitamin D are 50 per cent less likely to develop ... lines and hope it could also prevent other cancers. ... among women with high levels of vitamin D. ,The ...
... to four minutes of midday summer sun exposure to generate ... healthy, according to researchers from the Australian National University.// In ... found that just about 22 minutes of exposure to the ... of vitamin D. ,The researchers used ultraviolet radiation ...
... of Kaiser Permanente, overweight or obesity during one’s middle ... in life. ,'The study was presented during ... San Diego. ,The researchers from the Kaiser ... 9,000 people for a period of 30 years. ...
... are on the travel itinerary of Tibetan spiritual leader the ... ,The cities he will go to are Sao Paulo, the ... (Chile), Lima (Peru) and Bogota (Colombia). ,In Brazil, ... Chinese Mahayana Buddhist temple in South America located on the ...
Other Medicine News:
... The optomap is the companys core product. ... used in primary level eye care for the ... It is available on a pay-per-patient examination basis ... with a digital wide-field of view of the ...
... Compact Cardiac Digital Camera is a state-of-the-art, office-based ... gantry, and provides full sized fields of view. ... clinic you need a flexible system that can ... out how the Pulse reduces the costs of ...
... the same cryoconsole and platform technology as ... pulmonary veins. Arctic Circler is an ablation ... treatments that rely on medication., ,With ... has the ability to create curvilinear lesions ...
... The Guglielmi Detachable Coil is intended for: ... because of,their morphology, their location, or the ... by the treating,neurosurgical team to be a) ... operative techniques, or b) inoperable.,The GDC is ...
Medicine Products: